LIBRE-2: Efficacy of Lifestyle Intervention in BRCA1/2 Mutation Carriers
Study Details
Study Description
Brief Summary
The hypothesis of this 3 year, prospective randomized multicenter efficacy trial is that a structured life-style intervention program with exercise training and mediterranean diet is effective regarding increased adherence to a mediterranean diet, reduction of body mass index, and increase of physical fitness.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
BRCA1/2 mutation carriers have a considerably increased risk to develop breast and ovarian cancer during their lifetime. There is evidence from the literature that for sporadic breast cancer disease risk and the course of disease can be significantly influenced by physical activity, nutrition and weight. The hypothesis of this 3 year, prospective randomized multicenter efficacy trial is that a structured life-style intervention program with exercise training and mediterranean diet is effective regarding increased adherence to a mediterranean diet, reduction of body mass index, and increase of physical fitness.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| No Intervention: Control Study participants are instructed regarding a healthy diet according to the recommendations of the German Nutrition Society (DGE) and are informed about positive effects of physical activity on incidence and prognosis of breast cancer |
|
| Experimental: Intervention Structured exercise training plus mediterranean diet: Study participants receive a lifestyle intervention of 12 months duration (3 months intensive intervention plus 9 months maintenance using monthly contacts and meetings). The intervention comprises a structured intensified training based on the results of physical performance diagnostics and a nutrition program based on a mediterranean diet. |
Behavioral: Structured exercise training plus mediterranean diet
Structured exercise training plus mediterranean diet
|
Outcome Measures
Primary Outcome Measures
- Mediterranean Diet Adherence Screener (MEDAS) Score (Questionnaire) [12 months]
Adherence to mediterranean diet
- body mass index (BMI) [12 months]
Body weight (in kilograms) divided by body height (in meters) squared.
- ventilatory threshold 1 (VT1) in spiroergometry [12 months]
ventilatory threshold VT1 in spiroergometry
Secondary Outcome Measures
- stress coping capacity, as measured by the Trier Inventory for Chronic Stress (TICS) questionnaire [3, 12, 24, 36 months]
(TICS) questionnaire
- grade of optimism, as measured by the Life Orientation Test (LOT) questionnaire [3, 12, 24, 36 months]
Life Orientation Test (LOT)
- attitudes and beliefs regarding physical training and healthy diet, as measured by the "Bewertung körperlicher Aktivität und Ernährung" (BKAE) questionnaire [3, 12, 24, 36 months]
(BKAE) questionnaire
- quality of life, as measured by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) [3, 12, 24, 36 months]
(EORTC QLQ-C30)
- maximum oxygen consumption (VO2max), as measured by spiroergometry [3, 12 months]
spiroergometry
- physical activity, as measured by the International Physical Activity Questionnaire (IPAQ) [3, 12, 24, 36 months]
Physical Activity
- incidence of breast cancer [12, 24, 36 months]
During study
- Mediterranean Diet Adherence Screener (MEDAS) Score [3, 6, 9, 12, 24, 36 months]
(MEDAS) Score
- body mass index (BMI) [3, 12, 24, 36 months]
(BMI)
- change of maximum oxygen consumption (VO2max) at ventilation threshold 1 (VT1), as measured by spiroergometry [3, 12 months]
spiroergometry
- mortality rate [12, 24, 36 months]
During study
- satisfaction (questionnaire) [3, 12, 24, 36 months]
satisfaction (questionnaire)
- tobacco consumption [12, 24, 36 months]
survey
- alcohol consumption [12, 24, 36 months]
survey
- dietary habits and calory intake, as measured by the European Prospective Investigation into Cancer and Nutrition Study Food Frequency Questionnaire (EPIC-FFQ) [3, 12, 24, 36 months]
(EPIC-FFQ)
- serum cholesterol, serum high density lipoprotein cholesterol,serum, serum Glucose, triglycerides, c-reactive Protein, serum Insulin,proneurotensin [3, 12, 24, 36 months]
Blood Test
- proenkephalin [3, 12, 24, 36 months]
Genetic test
- Omega 3 fatty acid in the erythrocyte Membrane, Omega 6 fatty acid level in the erythrocyte Membraserum low density, lipoprotein cholesterolne, Omega 9 fatty acid level in the erythrocyte Membrane, [3, 12, 24, 36 months]
Blood Test
Eligibility Criteria
Criteria
Inclusion Criteria:
-
proven pathogenic BRCA1/2 mutation
-
age >=18
-
written informed consent
Exclusion Criteria:
-
current chemotherapy of radiotherapy (inclusion 6 weeks after CTX or RX possible)
-
metastatic tumor disease
-
life expectancy <3 years
-
clinically limiting cardiovascular or respiratory disease (instable CVD, heart failure stage IV, COPD GOLD IV, maximum resting blood pressure 160/100 mmHg)
-
significant orthopedic disability which prevents from participating in the group interventions
-
severe concomitant diseases which prevents from participating in the group interventions
-
Karnofsky index <60
-
maximum exercise capacity <50 W
-
food allergies which prevent from mediterranean diet
-
vegan diet
-
body mass index <15 kg/m2
-
pregnancy
-
insufficient knowledge of German language
-
insufficient compliance
-
active participation in other interventional trials
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Humboldt Universität zu Berlin | Berlin | Germany | ||
| 2 | Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden | Dresden | Germany | ||
| 3 | Universitätsklinikum Düsseldorf | Düsseldorf | Germany | ||
| 4 | Kliniken Essen-Mitte | Essen | Germany | ||
| 5 | Universitätsklinikum Essen | Essen | Germany | ||
| 6 | Universitätsklinikum Freiburg | Freiburg | Germany | ||
| 7 | Universitätsmedizin Göttingen | Göttingen | Germany | ||
| 8 | Universitätsklinikum Hamburg-Eppendorf | Hamburg | Germany | ||
| 9 | Medizinische Hochschule Hannover | Hannover | Germany | ||
| 10 | Universitätsklinium Heidelberg | Heidelberg | Germany | ||
| 11 | Universitätsklinikum Schleswig-Holstein, Campus Kiel | Kiel | Germany | ||
| 12 | Uniklinikum Köln | Köln | Germany | ||
| 13 | Universitätsklinikum Leipzig | Leipzig | Germany | ||
| 14 | Technische Universität München | München | Germany | ||
| 15 | Universität Regensburg | Regensburg | Germany | ||
| 16 | Interdisziplinäres Brustzentrum am Diakonieklinikum | Stuttgart | Germany | ||
| 17 | Universitätsklinikum Tübingen | Tübingen | Germany | ||
| 18 | Universität Ulm | Ulm | Germany | ||
| 19 | Universitätsklinikum Würzburg | Würzburg | Germany |
Sponsors and Collaborators
- Technische Universität München
- University of Hohenheim
- University Hospital Schleswig-Holstein
- University of Leipzig
- University of Cologne
Investigators
- Study Director: Marion Kiechle, Prof. Dr., Technische Universität München
- Study Director: Martin Halle, Prof. Dr., Technische Universität München
- Study Director: Stephan C Bischoff, Prof. Dr., Universitaet Hohenheim, Stuttgart
- Study Director: Michael Siniatchkin, Prof. Dr., Universitätsklinikum Schleswig-Holstein, Campus Kiel
- Study Director: Markus Loeffler, Prof. Dr., University of Leipzig
- Study Director: Christoph Engel, PD Dr., University of Leipzig
- Study Director: Rita K Schmutzler, Prof. Dr., University of Cologne
- Study Director: Alfons Meindl, Prof. Dr., Technische Universität München
- Principal Investigator: Anne S Quante, Dr., Technische Universität München
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- LIBRE-2-20150626